Article
Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.
BMC pulmonary medicine - 19 May 2021
Yang Yang, Liu Qilong, Cao Lei, Sun Wei, Gu Xiaowei, Liu Bin, Xiao Na, Teng Fei, Li Xiaoli, Chen Meiji, Yu Weiguang, Lin Huanyi, Xu Guixing
Abstract excerpt
BACKGROUND: The purpose of this study was to compare the efficacy of osimertinib (OSI) versus afatinib (AFA) in patients with T790M-positive, non-small-cell lung cancer (NSCLC) and multiple central nervous system (CNS) metastases after failure of initial epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. METHODS: Consecutive patients with T790M-positive NSCLC and multiple CNS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.